In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Case series of a rare association of cyanotic congenital heart disease with hypertrophic cardiomyopathy

Session Poster session 1

Speaker Arunachalam Pudhiavan

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P184

Authors : A Pudhiavan (Bangalore,IN), VIMAL Raj (Bangalore,IN), RICHA Kothari (Bangalore,IN), GA Karthik (Bangalore,IN), G Kannan (Bangalore,IN), S Shankar Maiya (Bangalore,IN), P V Suresh (Bangalore,IN), DEVI Prasad Shetty (Bangalore,IN)

Authors:
A Pudhiavan1 , VIMAL Raj1 , RICHA Kothari1 , GA Karthik1 , G Kannan1 , S Shankar Maiya2 , P V Suresh2 , DEVI Prasad Shetty2 , 1Narayana Institute of cardiac sciences, Cardiac Radiology - Bangalore - India , 2Narayana Institute of cardiac sciences - Bangalore - India ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii144

Introduction: Tetralogy of Fallot (TOF) is the most common among the cyanotic congenital heart disease. Congenital cardiac defects are often associated with other cardiac and non cardiac pathologies. However, the association of cyanotic heart disease with hypertrophic cardiomyopathy (HCM) is rare. This association carries a high incidence of sudden cardiac death and needs to be considered while managing these patients.

Purpose: To demonstrate the spectrum of imaging findings in CT and cardiac MR showing a rare association of congenital heart disease with hypertrophic cardiomyopathy phenotype.

Methods: The case series consists of 6 patients with known cyanotic congenital heart disease associated with hypertrophic cardiomyopathy phenotype. Out of 6, 3 are TOF, one transposition of great arteries and 2 atrial septal defects. All the patients were evaluated with cardiac magnetic resonance (MR) imaging except one, who underwent a cardiac CT. Native T1 mapping was done using a modified look locker inversion recovery (MOLLI) sequence.

Results: These patients, in addition to the septal defects causing right to left shunts, had classical imaging features of HCM with outflow tract / cavity obstruction and myocardial fibrosis. Five patients demonstrated narrowing of both the right and left ventricular outflow tracts. Post contrast late gadolinium enhanced (LGE) images revealed areas of myocardial scarring in 3 of these patients. All five patients who underwent CMR revealed elevated native T1 values suggesting myocardial fibrosis.

Conclusion: Hypertrophic cardiomyopathy is typically an isolated cardiac pathology, although there have been rare reports of its association with other entities. In this case series, we have showed its association with cyanotic congenital heart disease. The presence of HCM with outflow obstruction complicates the presentation of these congenital heart diseases and identification of this association is important in the treatment planning and prognostication.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are